Progressive Supranuclear Palsy – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Progressive Supranuclear Palsy – Pipeline Review, H2 2019’, provides an overview of the Progressive Supranuclear Palsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy

– The report reviews pipeline therapeutics for Progressive Supranuclear Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Progressive Supranuclear Palsy therapeutics and enlists all their major and minor projects

– The report assesses Progressive Supranuclear Palsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy ”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AbbVie Inc

Alterity Therapeutics Ltd

AlzProtect SAS

Arvinas Inc

Asceneuron SA

AZTherapies Inc

Biogen Inc

Cerebrum Therapeutics Inc

Cortice Biosciences Inc

Declion Pharmaceuticals Inc

EmeraMed Ltd

K-Stemcell Co Ltd

Merck & Co Inc

New Amsterdam Sciences Inc

Prothena Corp Plc

Retrotope Inc

TauRx Therapeutics Ltd

UCB SA

Voyager Therapeutics Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Progressive Supranuclear Palsy Overview

Progressive Supranuclear Palsy Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Progressive Supranuclear Palsy Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Progressive Supranuclear Palsy Companies Involved in Therapeutics Development

AbbVie Inc

AlzProtect SAS

Asceneuron SA

Biogen Inc

Cortice Biosciences Inc

Intellect Neurosciences Inc

K-Stemcell Co Ltd

Merck & Co Inc

Prana Biotechnology Ltd

Prothena Corp Plc

UCB SA

Voyager Therapeutics Inc

Progressive Supranuclear Palsy Drug Profiles

ABBV-8E12 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-120290 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-2006 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DC-TAB Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-016 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy To Inhibit Tau for Dementia and Neurodegenerative Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gosuranemab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydromethylthionine mesylate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8719 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Tau for Neurology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal antibody to Inhibit TauC3 for CNS Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBT-434 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Spinal Cord Injury, Alzheimer's Disease, Progressive Supranuclear Palsy and Cerebral Palsy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolfenamic acid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPI-287 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCB-0107 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Progressive Supranuclear Palsy Dormant Projects

Progressive Supranuclear Palsy Product Development Milestones

Featured News & Press Releases

Nov 03, 2017: Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer’s Disease and Related Tauopathies

May 04, 2017: AlzProtect : The American Food and Drug Administration (FDA) Has Granted AZP2006 the Orphan Drug Designation for the Treatment of Progressive Supranuclear Palsy (PSP)

Apr 04, 2017: Asceneuron Receives Approval for Phase I Study of Oral Tau Inhibitor

Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy

Oct 13, 2016: C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy

Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy

Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Progressive Supranuclear Palsy, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Progressive Supranuclear Palsy – Pipeline by AbbVie Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by Alterity Therapeutics Ltd, H2 2019

Progressive Supranuclear Palsy – Pipeline by AlzProtect SAS, H2 2019

Progressive Supranuclear Palsy – Pipeline by Arvinas Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by Asceneuron SA, H2 2019

Progressive Supranuclear Palsy – Pipeline by AZTherapies Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by Biogen Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by Cerebrum Therapeutics Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by Cortice Biosciences Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by Declion Pharmaceuticals Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by EmeraMed Ltd, H2 2019

Progressive Supranuclear Palsy – Pipeline by K-Stemcell Co Ltd, H2 2019

Progressive Supranuclear Palsy – Pipeline by Merck & Co Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by New Amsterdam Sciences Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by Prothena Corp Plc, H2 2019

Progressive Supranuclear Palsy – Pipeline by Retrotope Inc, H2 2019

Progressive Supranuclear Palsy – Pipeline by TauRx Therapeutics Ltd, H2 2019

Progressive Supranuclear Palsy – Pipeline by UCB SA, H2 2019

Progressive Supranuclear Palsy – Pipeline by Voyager Therapeutics Inc, H2 2019

Progressive Supranuclear Palsy – Dormant Projects, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Progressive Supranuclear Palsy, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports